Is Pegasys Still the Standard of Care for Hepatitis C?
No, Pegasys (peginterferon alfa-2a) is no longer the standard of care for hepatitis C. Direct-acting antivirals (DAAs) like sofosbuvir/velpatasvir (Epclusa) or glecaprevir/pibrentasvir (Mavyret) have replaced interferon-based regimens since around 2014, achieving cure rates over 95% with 8-12 week oral courses and minimal side effects.[1][2]
Why Did Treatments Shift Away from Pegasys?
Pegasys, approved in 2002, was combined with ribavirin for chronic hepatitis C but required 24-48 weeks of injections, with cure rates of 40-80% depending on genotype and high rates of flu-like symptoms, anemia, and depression. DAAs target viral proteins directly, bypassing immune stimulation, and work across all genotypes without interferon.[3]
What Are the Current Standard Treatments?
Guidelines from AASLD-IDSA (updated 2023) recommend genotype-agnostic DAAs as first-line:
- Sofosbuvir/velpatasvir for 12 weeks (treatment-naive, no cirrhosis).
- Glecaprevir/pibrentasvir for 8 weeks (most patients).
These cure >98% of cases, per clinical trials like ASTRAL-1.[4][5]
| Treatment Era | Key Regimen | Cure Rate | Duration | Common Side Effects |
|---------------|-------------|-----------|----------|---------------------|
| Pre-2011 (Pegasys era) | PegIFN + ribavirin | 45-80% | 24-48 weeks | Flu-like, hemolytic anemia, neuropsychiatric |
| Post-2014 (DAA era) | Sofosbuvir-based or pangenotypic DAAs | >95% | 8-12 weeks | Headache, fatigue (mild) |
Are There Cases Where Pegasys Is Still Used?
Rarely. It's not recommended for new patients but may appear in decompensated cirrhosis or post-transplant settings if DAAs fail or are contraindicated. WHO and EASL guidelines exclude it from routine use.[6]
How Accessible Are Modern Hepatitis C Treatments?
DAAs cost $25,000-$80,000 per course in the US but have dropped via generics (sofosbuvir ~$300 globally). Insurance covers most cases; programs like AbbVie's patient assistance provide free Mavyret for uninsured.[7]
[1]: AASLD-IDSA Hepatitis C Guidance
[2]: NEJM: Sofosbuvir-Velpatasvir Trial
[3]: FDA Pegasys Label
[4]: AASLD 2023 Update
[5]: EASL Hepatitis C Guidelines
[6]: WHO Hepatitis C Guidelines 2022
[7]: Hepatitis C Drug Pricing Report